Interleukin 21 Augments the Hepatitis B Virus-Specific CD8+ T-cell Response in Vitro in Patients Coinfected with HIV-1.

Guangxu Ren,Stefan Esser,Christoph Jochum,Joerg F. Schlaak,Guido Gerken,Dirk Schadendorf,Ulf Dittmer,Gang Wu,Zhenghong Yuan,Joerg Timm
DOI: https://doi.org/10.1097/qad.0b013e328359b7ae
IF: 4.632
2012-01-01
AIDS
Abstract:Objectives: Hepatitis B virus (HBV) and HIV-1 share similar transmission routes, therefore, coinfection with both viruses is frequently observed. In HIV-1-infected patients reduced interleukin 21 (IL-21) serum levels have been reported, which may impair virus-specific CD8(+) T-cell responses.Design: The HBV-specific CD8(+) T cells in patients with and without HIV-1 coinfection were analyzed cross-sectionally and it was tested whether addition of IL-21 in vitro augments HBV-specific CD8(+) T-cell responses.Methods: Patients with persistent HBV monoinfection as well as HIV-1-positive patients with persistent or resolved HBV-infection were studied. The IL-21 serum levels were determined by ELISA and the HBV-specific CD8(+) T-cell response was determined after antigen-specific expansion by intracellular staining of interferon gamma.Results: The HBV-specific CD8(+) T-cell response was significantly higher in HIV-1-negative patients compared with HIV-1-positive patients. Interestingly, within the HIV-1-positive group the magnitude of the response did not differ between patients with chronic or resolved HBV-infection. The IL-21 serum levels were significantly lower in the HIV-1-positive group. Importantly, addition of IL-21 in vitro significantly increased the HBV-specific CD8(+) T-cell response in HIV-1-positive patients, whereas there was no beneficial effect of IL-21 on cells from HBV-monoinfected patients.Conclusion: HIV-1 coinfection is associated with a decreased HBV-specific CD8 T-cell response that can be partially rescued in vitro by addition of IL-21. (c) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
What problem does this paper attempt to address?